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Abstract
Background: Neck dissection has traditionally played an important role in the management of
patients with regionally advanced head and neck squamous cell carcinoma (HNSCC) treated with
radical radiotherapy alone. However, with the incorporation of chemotherapy in the therapeutic
strategy for advanced HNSCC and resultant improvement in outcome the routine use of post
chemo-radiotherapy neck dissection is being questioned.
Methods: Published data for this review was identified by systematically searching MEDLINE,
CANCERLIT & EMBASE databases from 1995 until date with restriction to the English language.
Results: There is lack of high quality evidence on the role of planned neck dissection in advanced
HNSCC treated with chemo-radiotherapy. A systematic literature search could identify only one
small randomized controlled trial (Level I evidence) addressing this issue, albeit with major
limitations. Upfront neck dissection followed by chemo-radiotherapy resulted in better disease-
specific survival as compared to chemoradiation only. Several single arm prospective and
retrospective reports were also identified with significant heterogeneity and often-contradictory
conclusions.
Conclusions: Planned neck dissection after radical chemo-radiotherapy achieves a high level of
regional control, but its ultimate benefit is limited to a small subset of patients only. Unless there
are better non-invasive ways to identify residual viable disease, the role of such neck dissection shall
remain debatable. A large randomized controlled trial addressing this issue is needed to clarify its
role and provide evidence-based answers.
Introduction
The optimal management of the neck in loco-regionally
advanced head & neck squamous cell carcinomas
(HNSCC) following primary chemo-radiotherapy
remains controversial [1,2]. Traditionally neck dissection
(Fig 1) was thought to improve neck control in patients
with regionally advanced disease (N2–N3 disease) treated
with radical radiotherapy alone [3,4]. However, with the
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for advanced HNSCC and resultant improvement in out-
come [5,6], the routine use of post chemo-radiotherapy
neck dissection is being questioned [7,8]. Some authors
recommend neck dissection for bulky nodal disease after
chemo-radiation as part of organ preservation protocol in
an elective manner, regardless of the response in the neck
provided the primary is controlled. Others argue that it is
an ineffective procedure and should be abandoned. Nev-
ertheless, most investigators agree that elective neck dis-
section be performed for patients with less than a
complete response in the neck after combined modality
therapy to optimize regional control. This review attempts
to provide the discerning reader a bird's eye view of the
available evidence on this controversial issue.
Methods
Literature search strategy
Published data for this review was identified by systemat-
ically searching the MEDLINE, CANCERLIT & EMBASE
databases from 1995 until date with restriction to the Eng-
lish language. "Head & Neck cancer" OR "HNSCC" was
combined with "chemo-radiotherapy" OR "chemo-radia-
tion" as Medical Subject Heading (MeSH) terms and each
of the following phrase used as text words: "adjuvant neck
dissection"; "planned neck dissection"; and "neck man-
agement". Relevant cross-references were also considered.
Results & Discussion
The evidence
There is only one small randomized control trial (Ameri-
can Society of Clinical Oncology [9] Level I evidence)
evaluating the role of planned neck dissection in
advanced HNSCC treated with primary chemo-radiother-
apy. Carinci [10] et al randomly assigned patients with
advanced unresectable HNSCC to either elective neck dis-
section followed by chemo-radiotherapy (Group I, n =
23) or chemo-radiotherapy alone (Group II, n = 31). The
two groups were reasonably well balanced for known
prognostic factors. The 2-and 5-year disease-specific sur-
vival rates significantly favored the surgical arm (52% and
26% for Group I versus 29% and 0% for Group II
respectively). A Cox regression analysis adjusted for T-
stage, N-stage, age and gender showed that only therapy
(Group I versus II) reached a positive and significant odds
ratio in association with the probability of death (p =
0.0366 in favor of neck dissection). This study however
suffers from major limitations. Firstly, the trial methodol-
ogy was not detailed adequately to assess the validity of
the interpretations. The investigators neither specified the
method of randomization (why was the distribution une-
qual in the two arms) nor about stratification on known
prognostic factors. Secondly, the numbers of patients in
each arm were too small to draw any definite conclusions
without ruling out an element of bias. Thirdly, the radio-
therapy delivery was suboptimal (only 60–65 Gy with
conventional fractionation) for sterilizing advanced
HNSCC, in which case the addition of neck dissection was
expected to improve outcome. Finally, since neck dissec-
tion was done upfront rather than after chemo-radiother-
apy, the results of this trial cannot be directly extrapolated
to the issue under consideration.
In absence of high quality evidence, the best available evi-
dence tempered with clinical judgment often guides deci-
sion-making. Two of the recently published reports
[11,12] somewhat at contradiction with each other are
briefly discussed to illustrate the dilemma.
Argiris [11] et al evaluated 131 patients with HNSCC hav-
ing N2–N3 disease treated on concurrent chemo-radio-
therapy protocols. Neck dissection was performed in 92
(70%) patients, either before (n = 31) or after chemo-radi-
otherapy (n = 61). With a median follow-up of 4.6 years,
the 5-year loco-regional progression-free-survival (PFS)
was significantly better in patients with planned neck dis-
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(88% versus 74% respectively, p = 0.02) The addition of
neck dissection to chemo-radiotherapy resulted in only
one neck failure in 92 patients (neck PFS 99%) versus six
neck failures in 39 patients (neck PFS 82%) not undergo-
ing neck dissection (p = 0.0007). Neck dissection was
however, not beneficial in patients with a complete clini-
cal response (CCR). Of the 92 patients with a CCR, 62
underwent neck dissection, of which only 1 relapsed in
the neck (neck PFS 98%). The neck PFS of 92% (2 neck
failures) in the 30 patients in CCR who did not undergo
neck dissection was not significantly different (p = 0.21).
On subset analysis, in patients with N3 disease (n = 27),
there was either a trend or a statistically significant advan-
tage in all the survival parameters for the neck dissection
arm. In contrast, in patients with N2 disease (n = 104),
only the neck control improved with neck dissection. The
local PFS, distant PFS, and the overall survival were simi-
lar irrespective of neck dissection. The authors concluded
that in patients with N3 stage and less than CCR it was
necessary to add neck dissection for optimal disease con-
trol, whereas in patients with N2 disease in CCR, neck
dissection could safely be omitted without compromising
outcome.
Brizel [12] et al identified 108 patients with nodal disease
from a cohort of 154 patients on concurrent chemo-radi-
ation protocols. A modified neck dissection was per-
formed in 65 (60%) of 108 patients. With a median
follow up of 4 years for surviving patients, the neck con-
trol rate was 100% for N1 patients irrespective of neck dis-
section being performed or not. Their disease-free-survival
(DFS) was 70% with no differences relative to neck dissec-
tion. In N2–N3 patients, a CCR was achieved in 43 (55%)
patients. Ten patients with local progression or systemic
dissemination were excluded from analysis. Of the 52
patients undergoing neck dissection in N2–N3 group,
only 1 regional relapse was seen, in contrast to 3 neck fail-
ures out of 16 in those not undergoing dissection (p =
0.05). The 4-year DFS was 75% for N2–N3 patients with
a CCR and neck dissection versus 53% for those with CCR
but no neck dissection (p = 0.08). The 4-year overall sur-
vival was also better for the dissection arm (77% versus
50% respectively, p = 0.04). The authors concluded that
the policy of neck dissection in patients with N2–N3 dis-
ease even in CCR is justified to optimize loco-regional
control and survival.
Apart from the afore-mentioned two reports, there are a
few reasonably large studies (involving >50 patients:
Table 1) and several smaller ones, both prospective and
retrospective published in the last decade trying to define
the benefit of such intervention with conflicting results
[2,7,13-24]. However, significant heterogeneity in selec-
tion criteria as well as variable treatment schedules and
response assessment methodology amongst these reports
introduces a great deal of bias precluding any definitive
conclusions.
The potential benefit of planned neck dissection after a
course of intensive chemo-radiotherapy in terms of
improved regional control with or without an impact on
survival needs to be weighed against the expected morbid-
ity associated with the surgical procedure [12,14,25]. One
argument put forward in favor of planned neck dissection
even for patients in CCR is the high rate of pathological
positivity (30%–50%) depending upon the meticulous-
ness of sectioning by the pathologist [14,17]. However, a
significant majority of them actually may represent micro-
scopic non-viable residual disease only, as has been dem-
onstrated by Strasser using Ki-67 proliferating index [26],
unlikely to relapse later. Proponents of neck dissection
also argue that the ultimate success rate of salvage neck
dissection after a relapse in the neck treated with full dose
chemo-radiotherapy is small, whereas the morbidity is
high [10,25]. In contrast, the morbidity of a planned neck
dissection is at best modest, when scheduled between 6–
12 weeks from end of chemo-radiotherapy [7,14,17],
which is supposed to be the time window between acute
and chronic radiation injury.
Conclusions & Recommendations
Planned neck dissection after radical chemo-radiotherapy
achieves a high level of regional control, but its ultimate
benefit is limited to a small subset of patients only. The
morbidity of such dissection is small, but significant. Its
impact on survival is yet to be completely realized. In the
majority of patients it is either unnecessary because there
is no residual disease in the neck or futile because of
unsalvageable primary recurrence or distant metastases.
Nevertheless, it is recommended that planned neck dis-
section be performed for patients with less than a com-
plete response in the neck after combined modality
therapy to optimize regional control, provided the pri-
mary is controlled and there is no evidence of distant
metastases. It should also be performed as part of salvage
surgery for locally persistent or residual disease at primary
site. The criterion for planned neck dissection for patients
with advanced nodal disease with a CCR in the neck fol-
lowing chemo-radiotherapy should incorporate not only
the nodal staging but also the actual size of the involved
lymph nodes. Unless there are better non-invasive ways to
identify residual viable disease, which could include func-
tional imaging like Positron Emission Tomography and
biological assays like hypoxia markers, the role of such
neck dissection shall remain debatable. A large rand-
omized controlled trial across several institutions address-
ing these issues is needed to clarify the role of planned
neck dissection in advanced HNSCC treated with primaryPage 3 of 5
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answers.
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